Research graph
References from Brain Penetration Optimization and Anti-neuroinflammation Evaluation of Potent 6-Methyl-7-azaindol-3-yl-quinazoline DYRK1A Inhibitors for Alzheimer’s Disease. Local targets link to admitted publications; unresolved targets remain external evidence.
Role of neuroinflammation in neurodegeneration development
10.1038/s41392-023-01486-5 · 2023 · External reference
AD genes and microglia phenotypes: does microglia phenotypic heterogeneity matter?
10.1002/alz.093420 · 2025 · External reference
Alzheimer’s genes in microglia: a risk worth investigating
10.1186/s13024-023-00679-4 · 2023 · External reference
Cell type specific gene expression profiles of the candidate genes for Alzheimer’s disease
10.1002/alz.069318 · 2022 · External reference
Microglial efferocytosis: Diving into the Alzheimer’s disease gene pool
10.1016/j.neuron.2022.10.015 · 2022 · External reference
Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration
10.1016/j.cell.2018.05.003 · 2018 · External reference
Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies
10.1038/s41392-024-01911-3 · 2024 · External reference
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
10.1038/s41392-023-01588-0 · 2023 · External reference
Microglia in Alzheimer’s disease
10.1083/jcb.201709069 · 2018 · External reference
Depletion of microglia with CSF1R inhibitor prevents tau aggregation in the mouse model Thy1P301S
10.1002/alz.075354 · 2023 · External reference
Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model
10.1038/s41467-019-11674-z · 2019 · External reference
Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5×FAD mouse model of Alzheimer’s disease
10.1186/s13024-018-0244-x · 2018 · External reference
A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer’s disease (AD)
10.1016/j.bmc.2024.117925 · 2024 · External reference
Dyrk1 inhibition improves Alzheimer’s disease-like pathology
10.1111/acel.12648 · 2017 · External reference
FRTX-02, a selective and potent inhibitor of DYRK1A, modulates inflammatory pathways in mouse models of psoriasis and atopic dermatitis
10.1016/j.jtauto.2022.100185 · 2023 · External reference
Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment
10.1016/j.joca.2019.05.006 · 2019 · External reference
Inhibition of Dyrk1A Attenuates LPS-Induced Neuroinflammation via the TLR4/NF-κB P65 Signaling Pathway
10.1007/s10753-022-01699-w · 2022 · External reference
Function and regulation of Dyrk1A: towards understanding Down syndrome
10.1007/s00018-009-0123-2 · 2009 · External reference
Interplay between DYRK1A dosage and aneuploidy-induced neuropathology in Down syndrome
10.1038/s42003-026-09902-6 · 2026 · External reference
LPS-Induced Inflammation Abolishes the Effect of DYRK1A on IκB Stability in the Brain of Mice
10.1007/s12035-018-1113-x · 2019 · External reference
MicroRNA-221-3p inhibits the inflammatory response of keratinocytes by regulating the DYRK1A/STAT3 signaling pathway to promote wound healing in diabetes
10.1038/s42003-024-05986-0 · 2024 · External reference
Inhibition of CDK4/6 regulates AD pathology, neuroinflammation and cognitive function through DYRK1A/STAT3 signaling
10.1016/j.phrs.2023.106725 · 2023 · External reference
Unusual function of the activation loop in the protein kinase DYRK1A
10.1016/s0006-291x(03)00148-7 · 2003 · External reference
Genetic knockdown of DYRK1A attenuates cognitive impairment, Aβ pathology, tauopathy and neuroinflammatory responses in mouse models of AD
10.3389/fimmu.2025.1661791 · 2025 · External reference
The novel DYRK1A inhibitor KVN93 regulates cognitive function, amyloid-beta pathology, and neuroinflammation
10.1016/j.freeradbiomed.2020.08.030 · 2020 · External reference
ANTI-INFLAMMATORY EFFECTS OF SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR IN NEURODEGENERATIVE MOUSE MODELS
10.1016/j.jalz.2019.06.4563 · 2019 · External reference
Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans
10.1002/mnfr.201300325 · 2014 · External reference
Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer’s disease
10.1111/acel.13000 · 2019 · External reference
Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer’s Disease Drug Candidate
10.1021/acs.jmedchem.3c01888 · 2023 · External reference
Discovery and Preclinical Development of SM15685, a Novel Highly Selective Oral DYRK1A/B Inhibitor as a Potential Therapeutic for Alzheimer’s Disease
10.1002/alz.087795 · 2024 · External reference
A novel DYRK1a inhibitor, DYR533, reduces tau pathology and TNF alpha in the 3×Tg-AD and PS19 mouse models
10.1002/alz.076499 · 2023 · External reference
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics
10.1021/acs.jmedchem.8b00185 · 2018 · External reference
Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors
10.1021/acs.jmedchem.1c01115 · 2021 · External reference
Aristolactam BIII, a naturally derived DYRK1A inhibitor, rescues Down syndrome-related phenotypes
10.1016/j.phymed.2021.153695 · 2021 · External reference
Discovery of ZJCK-6-46: A Potent, Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor for the Treatment of Alzheimer’s Disease
10.1021/acs.jmedchem.4c00483 · 2024 · External reference
Structural modifications that alter the P-glycoprotein efflux properties of compounds
10.1021/jm201136z · 2012 · External reference
Impact of Hydrogen Bonding on P-Glycoprotein Efflux Transport as Revealed by Evaluation of a De Novo Prediction Model
10.1021/acsmedchemlett.3c00376 · 2023 · External reference
How hydrogen bonds impact P-glycoprotein transport and permeability
10.1016/j.bmcl.2012.08.059 · 2012 · External reference
Model of P-Glycoprotein Ligand Binding and Validation with Efflux Substrate Matched Pairs
10.1021/acs.jmedchem.4c00139 · 2024 · External reference
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
10.1038/srep42717 · 2017 · External reference
Strategies for Structural Modification of Small Molecules to Improve Blood-Brain Barrier Penetration: A Recent Perspective
10.1021/acs.jmedchem.1c00910 · 2021 · External reference
Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability
10.3390/pharmaceutics13071103 · 2021 · External reference
New Drug Delivery Systems Developed for Brain Targeting
10.1007/s40265-022-01717-z · 2022 · External reference
ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery
10.1124/pharmrev.120.000025 · 2023 · External reference
Classification analysis of P-glycoprotein substrate specificity
10.1080/10611860310001648248 · 2003 · External reference
Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transportan update
10.1208/s12248-014-9668-6 · 2015 · External reference
Morpholine as ubiquitous pharmacophore in medicinal chemistry: Deep insight into the structure-activity relationship (SAR)
10.1016/j.bioorg.2020.103578 · 2020 · External reference
Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation
10.1021/acs.jmedchem.8b00658 · 2018 · External reference
Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor
10.1021/acs.jmedchem.9b01379 · 2020 · External reference
Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133
10.1021/acs.jmedchem.9b01624 · 2020 · External reference
Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors
10.1021/acs.jmedchem.1c00023 · 2021 · External reference
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B
10.1021/acs.jmedchem.1c00024 · 2021 · External reference
Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors
10.1021/acs.jmedchem.1c01141 · 2022 · External reference
Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B
10.1021/acs.jmedchem.3c00884 · 2023 · External reference
Design, synthesis, and structure-activity relationship studies of 6H-benzo[b]indeno[1,2-d]thiophen-6-one derivatives as DYRK1A/CLK1/CLK4/haspin inhibitors
10.1039/d4md00537f · 2025 · External reference
CLK inhibition alters tau splicing and has a neuroprotective effect in vitro
10.1002/alz.042805 · 2020 · External reference
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview
10.3390/ijms22116047 · 2021 · External reference
An overview of cdc2-like kinase 1 (Clk1) inhibitors and their therapeutic indications
10.1002/med.21928 · 2022 · External reference
Regulation of CLK1 Isoform Expression by Alternative Splicing in Activated Human Monocytes Contributes to Activation-Associated TNF Production
10.3390/cells14231925 · 2025 · External reference
Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer’s Disease and Down Syndrome
10.3233/jad-240078 · 2024 · External reference
Cannabidiol Analogue CIAC001 for the Treatment of Morphine-Induced Addiction by Targeting PKM2
10.1021/acs.jmedchem.3c01029 · 2023 · External reference
An update on the regulatory mechanisms of NLRP3 inflammasome activation
10.1038/s41423-021-00670-3 · 2021 · External reference
NLRP3 inflammasome in neuroinflammation and central nervous system diseases
10.1038/s41423-025-01275-w · 2025 · External reference
The involvement of NLRP3 inflammasome in CUMS-induced AD-like pathological changes and related cognitive decline in mice
10.1186/s12974-023-02791-0 · 2023 · External reference
Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development
10.1016/j.apsb.2022.03.009 · 2022 · External reference
Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics
10.3390/biomedicines10092055 · 2022 · External reference
Lipopolysaccharide-Induced Neuroinflammation as a Bridge to Understand Neurodegeneration
10.3390/ijms20092293 · 2019 · External reference
Lipopolysaccharide-Induced Model of Neuroinflammation: Mechanisms of Action, Research Application and Future Directions for Its Use
10.3390/molecules27175481 · 2022 · External reference
Pharmacokinetics, distribution, metabolism, excretion and safety characterization of ZJCK-6-72: novel DYRK1A inhibitor with optimized brain exposure for Alzheimer’s disease therapy
10.3389/fphar.2026.1792258 · 2026 · External reference
Effective handling of induced-fit motion in flexible docking
10.1002/prot.20931 · 2006 · External reference
Induced-Fit Docking Enables Accurate Free Energy Perturbation Calculations in Homology Models
10.1021/acs.jctc.2c00371 · 2022 · External reference
Molecular Dynamics Simulation for All
10.1016/j.neuron.2018.08.011 · 2018 · External reference
End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design
10.1021/acs.chemrev.9b00055 · 2019 · External reference
Unlocking the Conformational Secrets of DYRK1A Kinase With Computational Microscope: Exploring Phosphorylation-Driven Structural Dynamics
10.1002/jcc.70172 · 2025 · External reference
Unveiling the biophysical basis of DYRK kinase family isoform selectivity mechanism of Abemaciclib using computational approaches
10.1080/1062936x.2025.2552133 · 2025 · External reference
CLK inhibition alters tau splicing and has a neuroprotective effect in vitro
10.1002/alz.042805 · ExternalCitation · doi-reference
Cell type specific gene expression profiles of the candidate genes for Alzheimer’s disease
10.1002/alz.069318 · ExternalCitation · doi-reference
Depletion of microglia with CSF1R inhibitor prevents tau aggregation in the mouse model Thy1P301S
10.1002/alz.075354 · ExternalCitation · doi-reference
A novel DYRK1a inhibitor, DYR533, reduces tau pathology and TNF alpha in the 3×Tg-AD and PS19 mouse models
10.1002/alz.076499 · ExternalCitation · doi-reference
Discovery and Preclinical Development of SM15685, a Novel Highly Selective Oral DYRK1A/B Inhibitor as a Potential Therapeutic for Alzheimer’s Disease
10.1002/alz.087795 · ExternalCitation · doi-reference
AD genes and microglia phenotypes: does microglia phenotypic heterogeneity matter?
10.1002/alz.093420 · ExternalCitation · doi-reference
Unlocking the Conformational Secrets of DYRK1A Kinase With Computational Microscope: Exploring Phosphorylation-Driven Structural Dynamics
10.1002/jcc.70172 · ExternalCitation · doi-reference
An overview of cdc2-like kinase 1 (Clk1) inhibitors and their therapeutic indications
10.1002/med.21928 · ExternalCitation · doi-reference
Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans
10.1002/mnfr.201300325 · ExternalCitation · doi-reference
Effective handling of induced-fit motion in flexible docking
10.1002/prot.20931 · ExternalCitation · doi-reference
Function and regulation of Dyrk1A: towards understanding Down syndrome
10.1007/s00018-009-0123-2 · ExternalCitation · doi-reference
Inhibition of Dyrk1A Attenuates LPS-Induced Neuroinflammation via the TLR4/NF-κB P65 Signaling Pathway
10.1007/s10753-022-01699-w · ExternalCitation · doi-reference
LPS-Induced Inflammation Abolishes the Effect of DYRK1A on IκB Stability in the Brain of Mice
10.1007/s12035-018-1113-x · ExternalCitation · doi-reference
New Drug Delivery Systems Developed for Brain Targeting
10.1007/s40265-022-01717-z · ExternalCitation · doi-reference
Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development
10.1016/j.apsb.2022.03.009 · ExternalCitation · doi-reference
Morpholine as ubiquitous pharmacophore in medicinal chemistry: Deep insight into the structure-activity relationship (SAR)
10.1016/j.bioorg.2020.103578 · ExternalCitation · doi-reference
A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer’s disease (AD)
10.1016/j.bmc.2024.117925 · ExternalCitation · doi-reference
How hydrogen bonds impact P-glycoprotein transport and permeability
10.1016/j.bmcl.2012.08.059 · ExternalCitation · doi-reference
Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration
10.1016/j.cell.2018.05.003 · ExternalCitation · doi-reference
The novel DYRK1A inhibitor KVN93 regulates cognitive function, amyloid-beta pathology, and neuroinflammation
10.1016/j.freeradbiomed.2020.08.030 · ExternalCitation · doi-reference
ANTI-INFLAMMATORY EFFECTS OF SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR IN NEURODEGENERATIVE MOUSE MODELS
10.1016/j.jalz.2019.06.4563 · ExternalCitation · doi-reference
Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment
10.1016/j.joca.2019.05.006 · ExternalCitation · doi-reference
FRTX-02, a selective and potent inhibitor of DYRK1A, modulates inflammatory pathways in mouse models of psoriasis and atopic dermatitis
10.1016/j.jtauto.2022.100185 · ExternalCitation · doi-reference
Molecular Dynamics Simulation for All
10.1016/j.neuron.2018.08.011 · ExternalCitation · doi-reference
Microglial efferocytosis: Diving into the Alzheimer’s disease gene pool
10.1016/j.neuron.2022.10.015 · ExternalCitation · doi-reference
Inhibition of CDK4/6 regulates AD pathology, neuroinflammation and cognitive function through DYRK1A/STAT3 signaling
10.1016/j.phrs.2023.106725 · ExternalCitation · doi-reference
Aristolactam BIII, a naturally derived DYRK1A inhibitor, rescues Down syndrome-related phenotypes
10.1016/j.phymed.2021.153695 · ExternalCitation · doi-reference
Unusual function of the activation loop in the protein kinase DYRK1A
10.1016/s0006-291x(03)00148-7 · ExternalCitation · doi-reference
End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design
10.1021/acs.chemrev.9b00055 · ExternalCitation · doi-reference
Induced-Fit Docking Enables Accurate Free Energy Perturbation Calculations in Homology Models
10.1021/acs.jctc.2c00371 · ExternalCitation · doi-reference
Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors
10.1021/acs.jmedchem.1c00023 · ExternalCitation · doi-reference
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B
10.1021/acs.jmedchem.1c00024 · ExternalCitation · doi-reference
Strategies for Structural Modification of Small Molecules to Improve Blood-Brain Barrier Penetration: A Recent Perspective
10.1021/acs.jmedchem.1c00910 · ExternalCitation · doi-reference
Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors
10.1021/acs.jmedchem.1c01115 · ExternalCitation · doi-reference
Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors
10.1021/acs.jmedchem.1c01141 · ExternalCitation · doi-reference
Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B
10.1021/acs.jmedchem.3c00884 · ExternalCitation · doi-reference
Cannabidiol Analogue CIAC001 for the Treatment of Morphine-Induced Addiction by Targeting PKM2
10.1021/acs.jmedchem.3c01029 · ExternalCitation · doi-reference
Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer’s Disease Drug Candidate
10.1021/acs.jmedchem.3c01888 · ExternalCitation · doi-reference
Model of P-Glycoprotein Ligand Binding and Validation with Efflux Substrate Matched Pairs
10.1021/acs.jmedchem.4c00139 · ExternalCitation · doi-reference
Discovery of ZJCK-6-46: A Potent, Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor for the Treatment of Alzheimer’s Disease
10.1021/acs.jmedchem.4c00483 · ExternalCitation · doi-reference
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics
10.1021/acs.jmedchem.8b00185 · ExternalCitation · doi-reference
Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation
10.1021/acs.jmedchem.8b00658 · ExternalCitation · doi-reference
Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor
10.1021/acs.jmedchem.9b01379 · ExternalCitation · doi-reference
Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133
10.1021/acs.jmedchem.9b01624 · ExternalCitation · doi-reference
Impact of Hydrogen Bonding on P-Glycoprotein Efflux Transport as Revealed by Evaluation of a De Novo Prediction Model
10.1021/acsmedchemlett.3c00376 · ExternalCitation · doi-reference
Structural modifications that alter the P-glycoprotein efflux properties of compounds
10.1021/jm201136z · ExternalCitation · doi-reference
Role of neuroinflammation in neurodegeneration development
10.1038/s41392-023-01486-5 · ExternalCitation · doi-reference
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
10.1038/s41392-023-01588-0 · ExternalCitation · doi-reference
Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies
10.1038/s41392-024-01911-3 · ExternalCitation · doi-reference
An update on the regulatory mechanisms of NLRP3 inflammasome activation
10.1038/s41423-021-00670-3 · ExternalCitation · doi-reference
NLRP3 inflammasome in neuroinflammation and central nervous system diseases
10.1038/s41423-025-01275-w · ExternalCitation · doi-reference
Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model
10.1038/s41467-019-11674-z · ExternalCitation · doi-reference
MicroRNA-221-3p inhibits the inflammatory response of keratinocytes by regulating the DYRK1A/STAT3 signaling pathway to promote wound healing in diabetes
10.1038/s42003-024-05986-0 · ExternalCitation · doi-reference
Interplay between DYRK1A dosage and aneuploidy-induced neuropathology in Down syndrome
10.1038/s42003-026-09902-6 · ExternalCitation · doi-reference
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
10.1038/srep42717 · ExternalCitation · doi-reference
Design, synthesis, and structure-activity relationship studies of 6H-benzo[b]indeno[1,2-d]thiophen-6-one derivatives as DYRK1A/CLK1/CLK4/haspin inhibitors
10.1039/d4md00537f · ExternalCitation · doi-reference
Classification analysis of P-glycoprotein substrate specificity
10.1080/10611860310001648248 · ExternalCitation · doi-reference
Unveiling the biophysical basis of DYRK kinase family isoform selectivity mechanism of Abemaciclib using computational approaches
10.1080/1062936x.2025.2552133 · ExternalCitation · doi-reference
Microglia in Alzheimer’s disease
10.1083/jcb.201709069 · ExternalCitation · doi-reference
Dyrk1 inhibition improves Alzheimer’s disease-like pathology
10.1111/acel.12648 · ExternalCitation · doi-reference
Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer’s disease
10.1111/acel.13000 · ExternalCitation · doi-reference
ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery
10.1124/pharmrev.120.000025 · ExternalCitation · doi-reference
The involvement of NLRP3 inflammasome in CUMS-induced AD-like pathological changes and related cognitive decline in mice
10.1186/s12974-023-02791-0 · ExternalCitation · doi-reference
Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5×FAD mouse model of Alzheimer’s disease
10.1186/s13024-018-0244-x · ExternalCitation · doi-reference
Alzheimer’s genes in microglia: a risk worth investigating
10.1186/s13024-023-00679-4 · ExternalCitation · doi-reference
Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transportan update
10.1208/s12248-014-9668-6 · ExternalCitation · doi-reference
Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer’s Disease and Down Syndrome
10.3233/jad-240078 · ExternalCitation · doi-reference
Genetic knockdown of DYRK1A attenuates cognitive impairment, Aβ pathology, tauopathy and neuroinflammatory responses in mouse models of AD
10.3389/fimmu.2025.1661791 · ExternalCitation · doi-reference
Pharmacokinetics, distribution, metabolism, excretion and safety characterization of ZJCK-6-72: novel DYRK1A inhibitor with optimized brain exposure for Alzheimer’s disease therapy
10.3389/fphar.2026.1792258 · ExternalCitation · doi-reference
Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics
10.3390/biomedicines10092055 · ExternalCitation · doi-reference
Regulation of CLK1 Isoform Expression by Alternative Splicing in Activated Human Monocytes Contributes to Activation-Associated TNF Production
10.3390/cells14231925 · ExternalCitation · doi-reference
Lipopolysaccharide-Induced Neuroinflammation as a Bridge to Understand Neurodegeneration
10.3390/ijms20092293 · ExternalCitation · doi-reference
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview
10.3390/ijms22116047 · ExternalCitation · doi-reference
Lipopolysaccharide-Induced Model of Neuroinflammation: Mechanisms of Action, Research Application and Future Directions for Its Use
10.3390/molecules27175481 · ExternalCitation · doi-reference
Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability
10.3390/pharmaceutics13071103 · ExternalCitation · doi-reference
